Lancet Neurology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial..
23:1087-1096.
2024
-
Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021..
23:973-1003.
2024
-
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.
23:344-381.
2024
-
Secondary stroke prevention in people with atrial fibrillation: treatments and trials.
23:404-417.
2024
-
WHO considers multiple sclerosis treatments essential.
23:140-140.
2024
-
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
23:46-59.
2024
-
Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.
22:1140-1149.
2023
-
Global, regional, and national burden of spinal cord injury, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
22:1026-1047.
2023
-
Prevention of perioperative stroke in patients undergoing non-cardiac surgery.
22:946-958.
2023
-
Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
22:685-711.
2023
-
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
21:246-257.
2022
-
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
20:1012-1026.
2021
-
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
20:1027-1037.
2021
-
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
20:795-820.
2021
-
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
20:821-831.
2021
-
Correction to Lancet Neurol 2020; 19: 582–90.
19:e9-e9.
2020
-
Reappraisal of an ALS trial: unaccounted procedural risk.
19:717-718.
2020
-
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
19:582-590.
2020
-
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
18:459-480.
2019
-
Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
18:439-458.
2019
-
Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
18:376-393.
2019
-
Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
18:357-375.
2019
-
Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
18:269-285.
2019
-
Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
18:88-106.
2019
-
Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
18:56-87.
2019
-
Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
17:1061-1082.
2018
-
Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
17:1083-1097.
2018
-
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
17:1053-1060.
2018
-
Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
17:939-953.
2018
-
Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
17:954-976.
2018
-
Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data.
17:895-904.
2018
-
Rapid reversal of haematoma expansion associated with vitamin K antagonists.
15:535-537.
2016
-
A clinical approach to diagnosis of autoimmune encephalitis.
15:391-404.
2016
-
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.
15:174-184.
2016
-
Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial.
13:1177-1185.
2014
-
Embolic strokes of undetermined source: support for a new clinical construct–Authors' reply.
13:967-967.
2014
-
Embolic strokes of undetermined source: the case for a new clinical construct.
13:429-438.
2014
-
Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.
13:276-286.
2014
-
Anticoagulant therapy in acute brain ischaemia.
12:526-527.
2013
-
Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation.
11:1066-1081.
2012
-
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies.
11:951-962.
2012
-
Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.
11:512-520.
2012
-
Reducing the risk of recurrent stroke in patients with AF.
11:479-481.
2012
-
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
11:225-231.
2012
-
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
10:969-977.
2011
-
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
10:436-445.
2011
-
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
10:43-53.
2011
-
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
9:1157-1163.
2010
-
B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial.
9:855-865.
2010
-
Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.
9:273-284.
2010
-
Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study.
8:530-536.
2009
-
Tackling the global burden of stroke: the need for large-scale international studies.
8:306-307.
2009
-
Erratum.
7:985-985.
2008
-
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.
7:875-884.
2008
-
What do the results of the PRoFESS trial teach us?.
7:860-862.
2008
-
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative..
6:857-868.
2007
-
The complex genetics of amyotrophic lateral sclerosis.
6:291-292.
2007
-
Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study.
5:749-754.
2006
-
Comparison studies of cholinesterase inhibitors for Alzheimer's disease.
3:622-626.
2004
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)